The goal of this program is to improve management of early breast cancer (BC) with anthracyclines and anthracycline alternatives. After hearing and assimilating this program, the clinician will be better able to: 1. Identify optimal candidates for chemotherapy through use of genomic assay scoring. 2. Weigh benefits vs risks associated with use of anthracycline-containing regimens in patients with BC. 3. Appraise evidence supporting the use of nonanthracycline-containing regimens for patients with human epidermal growth factor receptor 2-positive BC.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 903 Queens Lane
Pricing
CME included with membership · $1,095/yr
| Platinum Membership | $1,095/yr |
Collected from the provider’s public pages · source
Specialties served/covered
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Breast Imaging
- Cardiac Anesthesia
- Cardiovascular Disease
- Clinical Cardiac Electrophysiology
- Critical Care Medicine
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Facial Plastic & Reconstructive Surgery
- Gastroenterology
- General Internal Medicine
- General Operative Anesthesia
- General Otolaryngology
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Head & Neck Surgery
- Hematology
- Hospice & Palliative Medicine
- Hospital Medicine
- Interventional Radiology
- Laryngology
- Medical Oncology
- Neonatal-Perinatal Medicine
- Nephrology
- Neuro Anesthesia
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neuroradiology
- Nuclear Medicine
- Obstetric Anesthesia
- Otology & Neurotology
- Pain Medicine
- Pediatric Anesthesia
- Pediatric Cardiology
- Pediatric Critical Care Medicine
- Pediatric Emergency Medicine
- Pediatric Gastroenterology
- Pediatric Hematology-Oncology
- Pediatric Infectious Diseases
- Pediatric Neurology
- Pediatric Otolaryngology
- Pediatric Radiology
- Pediatric Surgery
- Primary Care Sports Medicine
- Pulmonary Disease
- Regional Anesthesia & Acute Pain
- Rheumatology
- Rhinology
- Sleep Medicine
- Surgical Critical Care
- Surgical Oncology
- Thoracic Anesthesia
- Trauma Surgery
- Vascular Surgery
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Radiology
- Sports & Exercise Medicine
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Membership pricing — $1,095 / year
This provider prices CME through membership. Individual courses may also be sold separately.
See plans on audio-digest.orgListed by the provider
- Enduring / On-demand
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Membership pricing
-
ReleasedSep 1, 2026
-
Last day to claim creditSep 22, 2027 11 months left
-
Learner’s Digest International (TM) From Clinical Hematology and Oncology 2024, Presented By Scripps Health
-
Learner’s Digest International (TM) CDK4/6 Inhibitor Therapy in Early-stage HR+/HER2+ Breast Cancer
-
Learner’s Digest International (TM) Management of Cardiotoxicity in the Treatment of Breast Cancer
-
Clinical Care Options, LLC (dba Decera Clinical Education) Key Studies in Breast Cancer: Independent Conference Coverage of the 2026 ASCO Annual Meeting
-
Medical Learning Institute, Inc. Oncologist Voices from the Frontline: Adjuvant CDK4/6 Therapy in HR+ HER2- Breast Cancer
-
Answers in CME Inc. (AiCME) Bridging Clinic and OR: A Dialogue on the Emerging Role of Neoadjuvant HER2-Directed ADCs in HER2+ Breast Cancer
